Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 3/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25613142 | 0.80 | PIK3CA (0.38) | PIK3CAPIK3CDMTOR | |
| SCHEMBL25613148 | 0.75 | KDM4E (0.38) | — | |
| SCHEMBL25613161 | 0.75 | KDM4E (0.40) | — | |
| SCHEMBL25625249 | 0.75 | — | — | |
| SCHEMBL25613160 | 0.74 | ALOX15 (0.41) | PIK3CAMTOR | |
| SCHEMBL25627935 | 0.74 | PIK3CA (0.31) | PIK3CAPIK3CDMTOR | |
| SCHEMBL25613150 | 0.72 | ULK1 (0.31) | PIK3CAPIK3CDMTOR | |
| SCHEMBL25627937 | 0.69 | CNR2 (0.30) | — | |
| SCHEMBL25613158 | 0.68 | MAP3K11 (0.36) | — | |
| SCHEMBL25613146 | 0.65 | CACNA1G (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | BCL2, BCL2L2, BCL2L1 | PIK3CA 1141/4885PIK3CD 965/4885MTOR 964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.